WINSTON-SALEM, N.C. – Based on their surprising discovery that an obesity drug can kill cancer cells, scientists at Wake Forest University School of Medicine have made a new finding about the drug’s effects and are working to design more potent cancer treatments.
Published online this month in Nature Structural and Molecular Biology, the study is the first to report how the drug orlistat (Xenical® or Alli®) binds and interacts with a protein found in tumor cells. The drug blocks the protein’s function and causes cell death.
The project started five years ago when Steven Kridel, Ph.D., an assistant professor in the Department of Cancer Biology, analyzed prostate cancer cells to see which enzymes were expressed at high levels. His hope was that treatments to inhibit those enzymes could also stop tumor growth.
“We found that a protein known as fatty acid synthase is expressed at high levels in prostate tumor cells, and is fairly absent in normal cells,” said Kridel.
Other research has shown that the protein is found in many tumor cells including breast, colon, ovarian, liver, lung and brain.
“High levels of fatty acid synthase correlate with a poor prognosis so it is a great treatment target,” said Kridel. “This makes an exciting treatment target because theoretically you don’t have to worry about harming nearby healthy tissue.”
Unfortunately, orlistat itself cannot be used as a cancer treatment because, while it can kill cancer cells in the laboratory, in humans it is designed to act only in the digestive tract.
“Understanding this drug-protein interaction is essential for designing new drugs,” said W. Todd Lowther, Ph.D., an assistant professor in the Department of Biochemistry. “We’ve used a technique known as X-ray crystallography and now have a three-dimensional snapshot of the drug interacting with the protein.”
“Our goal is to develop an orlistat-like drug that can get into the bloodstream and go to the site of a tumor,” said Lowther.
Once they developed the three-dimensional map of the interaction, Lowther and Kridel began screening hundreds of thousands of compounds to identify those that interact with cancer cells in the same way as orlistat. They have narrowed the list of possibilities down to a dozen and will now work to optimize the compounds in hopes of creating potent cancer treatments. The drugs will first be tested in animals and then in human cancer patients.
Fatty acid synthase is also found in fat cells, which suggests that if the scientists are successful in developing an anti-cancer drug, it could also be an effective obesity drug.
“You might have the same drug for treating a cancer patient as an obese patient,” said Lowther.
The study was supported by the Department of Defense Prostate Cancer Research Program and the National Institutes of Health.
Co-researchers were graduate student Charles W. Pemble, IV, B.S., lead author, and Lynnette C. Johnson, B.S., both with Wake Forest.
Media Contacts: Karen Richardson, firstname.lastname@example.org; Shannon Koontz, email@example.com; and Bonnie Davis, firstname.lastname@example.org, at 336-716-4587.
Wake Forest University Baptist Medical Center is an academic health system comprised of North Carolina Baptist Hospital and Wake Forest University Health Sciences, which operates the university’s School of Medicine. U.S. News & World Report ranks Wake Forest University School of Medicine 18th in family medicine, 20th in geriatrics, 25th in primary care and 41st in research among the nation's medical schools. It ranks 35th in research funding by the National Institutes of Health. Almost 150 members of the medical school faculty are listed in Best Doctors in America